TORONTO – April 27, 2026 – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) has announced a strategic move to enhance its market presence and shareholder engagement by retaining the services of two specialized firms: Senergy Communications Capital Inc. (“Senergy”) and King Tide Media LLC (“KTM”). These agreements, effective in May 2026, are designed to amplify corporate branding, expand social media reach, and foster more robust dialogues with investors and market participants.
Marketing and Investor Awareness Initiatives
Quantum BioPharma, a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, is investing in targeted outreach. The company has engaged Senergy Communications Capital Inc. on a one-month contract, with an option for renewal, commencing May 18, 2026. Senergy, a Vancouver-based firm specializing in marketing, advertising, and shareholder relations, will be responsible for designing and executing campaigns aimed at increasing corporate branding and investor awareness. These initiatives will encompass social media strategies and broader advertising efforts.
Under the terms of its agreement, Quantum BioPharma will pay Senergy USD $150,000. This amount includes a service fee of USD $25,000 and USD $125,000 allocated for advertising expenses. The company stated that, to its knowledge, Senergy does not currently own any shares, options, or warrants in Quantum BioPharma, indicating an arm’s-length relationship.
Senergy Communications Capital Inc. Contact Details:
- Address: 1122 Mainland Street #228, Vancouver, BC V6B 5L1
- Email: aleem@senergy.capital
- Website: www.senergy.capital
- Phone: (778) 772-6740
In parallel, Quantum BioPharma has also retained King Tide Media LLC (“KTM”) for a one-month contract, also with an option for renewal, beginning May 1, 2026. KTM, based in Lake Worth, Florida, is similarly focused on market awareness and cultivating productive, ongoing dialogues with the company’s shareholders and other stakeholders in the market. Like Senergy, KTM will be tasked with developing and implementing campaigns that include corporate branding, social media engagement, and advertising initiatives.
The financial terms for KTM’s services stipulate a payment of USD $125,000 from Quantum BioPharma. The company has also confirmed that, to its knowledge, KTM does not hold any shares, options, or warrants in Quantum BioPharma, reinforcing the arm’s-length nature of this engagement.
King Tide Media LLC Contact Details:
- Address: 806E Windward Way #616, Lantana, Florida, 33462
- Email: james@kingtidemedia.net
- Website: https://kingtidemedia.net/
- Phone: (843) 368-7691
Quantum BioPharma’s Development Pipeline
Quantum BioPharma’s strategic focus remains on building a robust portfolio of innovative assets and biotech solutions. The company is particularly invested in addressing challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates currently in various stages of development. A key component of its pipeline is through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”).
Lucid is actively engaged in the research and development of its lead compound, Lucid-MS. This patented new chemical entity has demonstrated potential in preclinical models to prevent and reverse myelin degradation, which is identified as the underlying mechanism of multiple sclerosis. The advancement of Lucid-MS represents a significant area of focus for Quantum BioPharma’s therapeutic ambitions.
Furthermore, Quantum BioPharma has a stake in the consumer wellness market through its involvement with Unbuzzd Wellness Inc. (“UWI”). The company previously invented the product unbuzzd and subsequently spun out its over-the-counter version to UWI, a venture led by industry veterans. As of December 31, 2025, Quantum BioPharma retains an ownership stake of 19.84% in UWI. The agreement with UWI also includes provisions for royalty payments, entitling Quantum BioPharma to 7% of sales from the unbuzzd™ product until the total payments reach USD $250 million. Following this threshold, the royalty rate is set to decrease to 3% in perpetuity. Importantly, Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical applications, separating its consumer and clinical development strategies.
The engagement of Senergy Communications Capital Inc. and King Tide Media LLC signifies Quantum BioPharma’s commitment to proactively communicating its progress and strategic direction to the investment community, aiming to foster greater understanding and support for its ongoing development efforts in the biopharmaceutical sector.
